Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats

European Journal of Pharmacology

Volumn 571, Issue 2-3, 2007, Pages 215-221

  Chapman, Richard W ^a   House, Aileen ^a   Jones, Howard ^a   Richard, Jennifer ^a   Celly, Chander ^a   Prelusky, Dan ^a   Ting, Pauline ^a   Hunter, John C ^a   Lamca, James ^a   Phillips, Jonathan E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dry powder aerosol; Inflammation; Inhaled; Lung function; Roflumilast

Indexed keywords

ALLERGEN; BETAMETHASONE; OVALBUMIN; ROFLUMILAST; SALBUTAMOL;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FORCED EXPIRATORY VOLUME; LUNG FUNCTION; LUNG LAVAGE; NONHUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, INHALATION; AMINOPYRIDINES; ANIMALS; ANTI-ALLERGIC AGENTS; BENZAMIDES; BRONCHOALVEOLAR LAVAGE FLUID; CYCLOPROPANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; LUNG; OVALBUMIN; PEAK EXPIRATORY FLOW RATE; PHOSPHODIESTERASE INHIBITORS; PULMONARY EDEMA; RATS; RATS, INBRED BN; RESPIRATORY HYPERSENSITIVITY; TIME FACTORS; VITAL CAPACITY;

EID: 34548595642     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.074     Document Type: Article

References (27)

1. Beckmann N., Tigani B., Ekatodramis D., Borer R., Mazzoni L., and Fozard J.R. Pulmonary edema induced by allergen challenge in the rat: non-invasive assessment by magnetic resonance imaging. Magn. Reson. Med. 45 (2001) 88-95
2. Billah M.M., Cooper N., Minnicozzi M., Warneck J., Wang P., Hey J.A., Kreutner W., Rizzo C.A., Smith S.R., Young S., Chapman R.W., Dyke H., Shih N.-Y., Piwinski J.J., Cuss F.M., Montana J., Ganguly A.K., and Egan R.W. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-qui noline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor. J. Pharmacol. Exp. Ther. 302 (2002) 127-137
3. Bousquet J., Aubier M., Sastre J., Izquierdo J.L., Adler L.M., Hofbauer P., Rost K.-D., Harnest U., Kroemer B., Albrecht A., and Bredenbröker D. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone diproprionate in the treatment of persistent asthma. Allergy 61 (2006) 72-78
4. Bundshuh D.S., Eltze M., Barsig J., Wollin L., Hatzelmann A., and Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297 (2001) 280-290
5. Celly C.S., House A., Jones H., Hey J.A., and Chapman R.W. Prevention and resolution of antigen-induced alterations in lung function of allergic Brown Norway rats by a PDE4 inhibitor, roflumilast. Am. J. Respir. Crit. Care Med. 12 (2005) A95
6. Celly C.S., House A., Sehring S.J., Xiang X.Y., Jones H., Hey J.A., Egan R.W., and Chapman R.W. Temporal profile of forced expiratory lung function in allergen-challenged Brown-Norway rats. Eur. J. Pharmacol. 540 (2006) 147-154
7. Chapman R.W., Sehring S.J., Garlisi C.G., Falcone A., Kung T.T., Stelts D., Minnicozzi M., Jones H., Umland S., Egan R.W., and Kreutner W. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneim. Forsch. Drug Res. 48 (1998) 384-391
8. Chung K.F. Phosphodiesterase inhibitors in airway disease. Eur. J. Pharmacol. 533 (2006) 110-117
9. Dietsch G.N., DiPalma C.R., Eyre R.J., Pham T.Q., Poole K.M., Pefaur N.B., Welch W.D., Trueblood E., Kerns W.D., and Kanaly S.T. Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol. Pathol. 34 (2006) 39-51
10. Giembycz M.A. An update and appraisal of the cilomilast Phase III clinical development program for chronic obstructive pulmonary disease. Br. J. Clin. Pharmacol. 62 (2006) 138-152
11. Hatzelmann A., and Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297 (2001) 267-279
12. Hsieh T.H., Yu C.P., and Oberdorster G. Deposition and clearance models of Ni compounds in the mouse lung and comparisons with the rat models. Aerosol Sci. Technol. 31 (1999) 358-372
13. Kumar R.K., Herbert C., Thomas P.S., Wollin L., Beume R., Yang M., Webb D.C., and Foster P.S. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J. Pharmacol. Exp. Ther. 307 (2003) 349-355
14. Kuss H., Hoefgen N., Johanssen S., Kronbach T., and Rundfeldt C. In vivo efficacy in airway disease models of N-(3,5-dichloropyyrid-4-yl)-[1-(4-flurobenzyl)-5-hydroxy-indole-3-yl]-gl yoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J. Pharmacol. Exp. Ther. 307 (2003) 373-385
15. Larson J.L., Pino M.V., Geiger L.E., and Simeone R. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol. 78 (1996) 44-49
16. Lin C.-C., Lin C.-Y., Liaw S.-F., and Chen A. Pulmonary function changes and immunomodulation of Th-2 cytokine expression induced by aminophylline after sensitization and allergen challenge in Brown Norway rats. Ann. Allergy, Asthma, & Immun. 88 (2002) 215-222
17. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
18. Losco P.E., Evans E.W., Barat S.A., Blackshear P.E., Reyderman L., Fine J.S., Bober L.A., Anthes J.C., Mirro E.J., and Cuss F.M. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol. Pathol. 32 (2004) 295-308
19. Raabe O.G., Al-Bayati M.A., Teague S.V., and Rasolt A. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann. Occup. Hyg. 32 (1988) S55-S63
20. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbröker D., and Bethke T.D. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 366 (2005) 563-571
21. Rennard S.I., Schachter N., Strek M., Rickard K., and Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129 (2006) 56-66
22. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63 (2003) 2575-2594
23. Stokes Peebles Jr. R., Permutt S., and Togias A. Rapid reversibility of the allergen-induced pulmonary late-phase reaction by an intravenous β2-agonist. J. Appl. Physiol. 84 (1998) 1500-1505
24. Tigani B., Schaeublin E., Sugar R., Jackson A.D., Fozard J.R., and Beckman N. Pulmonary inflammation monitored non-invasively by MRI in freely breathing rat. Biochem. Biophys. Res. Commun. 292 (2002) 216-221
25. Tigani B., Cannet C., Zurbrügg S., Schaeublin E., Mazzoni L., Fozard J.R., and Beckmann N. Resolution of the edema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging. Br. J. Pharmacol. 140 (2003) 239-246
26. Torphy T.J. Phosphodiesterase isoenzymes: molecular targets for novel anti-asthma agents. Am. J. Respir. Crit. Care Med. 157 (1998) 361-370
27. van Schalkwyk E., Strydom K., Williams Z., Venter L., Leichtl S., Schmid-Wirlitsch C., Bredenbröker D., and Bardin P.D. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol. 116 (2005) 292-298